GLP-1 Drugs in Organ Transplantation: Redefining Post-Transplant Care
Review explores whether GLP-1 drugs can redefine transplantation standard of care by addressing post-transplant diabetes, obesity, and cardiovascular risk in organ recipients.
Quick Facts
What This Study Found
Review explores whether GLP-1 drugs can redefine transplantation standard of care by addressing post-transplant diabetes, obesity, and cardiovascular risk in organ recipients.
Key Numbers
Review covers evidence across solid organ transplant types for GLP-1 drug benefits on metabolism and graft outcomes.
How They Did This
Methodology detailed in publication.
Why This Research Matters
Relevant to expanding peptide-based therapeutic applications.
The Bigger Picture
Contributes to the growing evidence for peptide therapeutics.
What This Study Doesn't Tell Us
Limitations in publication.
Questions This Raises
- ?Long-term implications?
- ?Comparison to existing evidence?
- ?Next research steps?
Trust & Context
- Key Stat:
- Key finding Review explores whether GLP-1 drugs can redefine transplantation standard of care by addressing post
- Evidence Grade:
- Based on study design in publication.
- Study Age:
- Published in 2025.
- Original Title:
- Can GLP-1RAs redefine transplantation standard of care?
- Published In:
- Trends in pharmacological sciences, 46(11), 1056-1071 (2025)
- Authors:
- Almalki, Bassem A
- Database ID:
- RPEP-09879
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What does this mean?
Review explores whether GLP-1 drugs can redefine transplantation standard of care by addressing post-transplant diabetes, obesity, and cardiovascular risk in organ recipients.
How reliable?
Consult publication and healthcare provider.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09879APA
Almalki, Bassem A. (2025). Can GLP-1RAs redefine transplantation standard of care?. Trends in pharmacological sciences, 46(11), 1056-1071. https://doi.org/10.1016/j.tips.2025.08.013
MLA
Almalki, Bassem A. "Can GLP-1RAs redefine transplantation standard of care?." Trends in pharmacological sciences, 2025. https://doi.org/10.1016/j.tips.2025.08.013
RethinkPeptides
RethinkPeptides Research Database. "Can GLP-1RAs redefine transplantation standard of care?" RPEP-09879. Retrieved from https://rethinkpeptides.com/research/almalki-2025-can-glp1ras-redefine-transplantation
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.